Drugs / CAR2219
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06911710 | Nov 2024 → Feb 2026 overdue | T lymphoblastic leukemia/lymphoma, T-cell non-Hodgkin lymphoma, acute myeloid leukemia, aggressive B-cell non-Hodgkin lymphoma +1 | Tianjin Medical University General Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR2219 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06911710 ↗ |
| Modality | Cell therapy | “CAR-T Cell Therapy” NCT06911710 ↗ |
| Route | Other | “CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）” NCT06911710 ↗ |